Company Quick10K Filing
Nutra Pharma
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 4,014 $0
10-Q 2018-11-19 Quarter: 2018-09-30
10-Q 2018-08-17 Quarter: 2018-06-30
10-Q 2018-05-21 Quarter: 2018-03-31
10-K 2018-04-17 Annual: 2017-12-31
10-Q 2017-11-20 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-17 Quarter: 2017-03-31
10-K 2017-04-17 Annual: 2016-12-31
10-Q 2016-11-22 Quarter: 2016-09-30
10-Q 2016-08-22 Quarter: 2016-06-30
10-Q 2016-05-27 Quarter: 2016-03-31
10-K 2016-04-14 Annual: 2015-12-31
10-Q 2015-11-23 Quarter: 2015-09-30
10-Q 2015-08-18 Quarter: 2015-06-30
10-Q 2015-05-19 Quarter: 2015-03-31
10-K 2015-04-13 Annual: 2014-12-31
10-Q 2014-11-14 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
10-Q 2014-05-20 Quarter: 2014-03-31
10-K 2014-03-31 Annual: 2013-12-31
10-Q 2013-11-19 Quarter: 2013-09-30
10-Q 2013-08-19 Quarter: 2013-06-30
10-Q 2013-05-20 Quarter: 2013-03-31
10-K 2013-04-16 Annual: 2012-12-31
10-Q 2012-12-05 Quarter: 2012-09-30
10-Q 2012-12-03 Quarter: 2012-06-30
10-Q 2012-11-21 Quarter: 2012-03-31
10-K 2012-11-13 Annual: 2011-12-31
10-Q 2011-11-15 Quarter: 2011-09-30
10-Q 2011-08-15 Quarter: 2011-06-30
10-Q 2011-05-16 Quarter: 2011-03-31
10-K 2011-04-01 Annual: 2010-12-31
10-Q 2010-11-15 Quarter: 2010-09-30
10-Q 2010-08-16 Quarter: 2010-06-30
10-Q 2010-05-21 Quarter: 2010-03-31
10-K 2010-04-15 Annual: 2009-12-31
8-K 2018-10-03 Accountant, Exhibits
8-K 2018-09-28 Regulation FD, Other Events, Exhibits
8-K 2018-02-23 Officers

Nutra Pharma Financials

NPHC Metrics, Comps, Filings

Annual | Quarterly

Business

We were incorporated in California on February 1, 2000. We have conducted our operations since October 2003. We are a biopharmaceutical company that engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. Homeopathic drugs are natural products that contain ingredients listed in the HPUS (Homeopathic Pharmacopoeia of the United States). An ethical drug is a licensed drug that has obtained Federal Drug Administration ("FDA") approval after extensive pre-clinical and clinical testing. We seek strategic licensing partnerships to reduce the risks associated with the drug development process.

Our wholly owned subsidiary and drug discovery arm, ReceptoPharm, has carried out our homeopathic and drug discovery research and clinical development and has fully developed four homeopathic drugs for the treatment of pain:

Nyloxin® and Nyloxin® Extra Strength


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Electromedical Technologies (ELCQ)
Natcore Technology (NXT)
Sunshine Biopharma (SBFM) 0 23% 0.0 -1,974% 109 926 372 85 -2,160 -1,984 -37
SmileDirectClub (SDC)
DigitalTown (DGTW) 0 12,618% 0.0 -16,557% 34 2,761 -2 -220 -5,706 -3,920 -34
Amplitude Healthcare (AMHCU)
Galileo Acquisition (GLEO)
GigCapital2 (GIX)
Tortoise Acquisition (SHLL)
Cantabio Pharmaceuticals (CTBO) 0 0.9 -474% 326 2,215 0 0 -1,543 -331 -283
Pioneer Bancorp (PBFS)
Anchiano Therapeutics (ANCN)
Life Clips (LCLP) 0 135% -0.7 -21,823% 16 9,270 -86 -116 -3,494 -3,182 2,355
Envista (NVST)
Angiosoma (SOAN) 0 90% -0.3 -465% 159 887 1 1 -739 -415 104
Merida Merger I (MCMJ)
Nutra Pharma (NPHC) 0 71% -0.2 -2,939% 252 5,614 106 75 -7,398 -6,591 1,498
GH Capital (GHHC) 0 66% -0.0 -2,680% 89 331 211 139 -2,374 -2,374 59
X Rail Entertainment (XREE) 0 -0.1 -1,534,597% 0 3,429 0 0 -5,601 -5,995 345
GIFA (FRFS) 0 63% -0.9 43% 80 362 98 62 34 34 -30

Balance Sheet ($'000)2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash8516731
Accounts Receivable3811127223115
Inventory0547542620
PP&E4018129191416
Assets303129387388214390
Accounts Payable8011,0191,2448429581,302
Long-Term Debt80330401,4231,926
Liabilities3,8794,3493,9823,9624,6915,800
Stockholders' Equity-3,576-4,219-3,595-3,574-4,477-5,410
Income Statement ($'000)2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue203122595291168121
Cost of Revenue14841114663927
Gross Profit5681480225-5594
R&D3
SG&A2,6542,4422,6825,9921,9891,476
Tax000000
Net Income-3,612-4,343-2,533-5,392-3,448-4,029
Cash Flow ($'000)2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-721-531-148-1,018-1,356-1,138
Cash Investing00-22-1-3-9
Cash Financing7295281811,0101,3841,116